Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
STOCKHOLM, 6 April 2018. Asarina Pharma, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company, has announced the start of a clinical Phase IIB study with the drug candidate...
-
STOCKHOLM, 6 April 2018. Asarina Pharma, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company, has announced the start of a clinical Phase IIB study with the drug candidate...
-
STOCKHOLM den 21 mars 2018. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att årsredovisningen för 2017 har offentliggjorts. Årsredovisningen finns nu tillgänglig på...
-
STOCKHOLM - 21 March 2018. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2017. The report is now available to download at...
-
Aktieägarna i Karolinska Development AB (publ), org.nr 556707-5048, ("Karolinska Development" eller "Bolaget"), kallas till årsstämma torsdagen den 26 april 2018, kl. 17.00 på Tomtebodavägen 23 A i...
-
The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, ("Karolinska Development" or the "Company") are invited to the Annual General Meeting, on Thursday April 26, 2018 at 5...
-
STOCKHOLM, 19 March 2018. Karolinska Development's portfolio company Forendo Pharma announces a €3 million loan grant decision by Business Finland. The purpose of the loan is to support the...
-
STOCKHOLM, 19 March 2018. Karolinska Development's portfolio company Forendo Pharma announces a €3 million loan grant decision by Business Finland. The purpose of the loan is to support the...
-
STOCKHOLM, 15 March 2018. Karolinska Development's portfolio company Modus Therapeutics, focused on sickle cell disease (SCD) and malaria, announces that Dr. John Öhd has been appointed to a...
-
STOCKHOLM, 15 March 2018. Karolinska Development's portfolio company Modus Therapeutics, focused on sickle cell disease (SCD) and malaria, announces that Dr. John Öhd has been appointed to a...